0001809519-26-000111
SEC filingQ1 revenue declined 4.4% to $194.0M amid pharmacy network disruptions from Rite Aid closures, partially offset by strong Pharma Direct growth, driving operating income down 40.1% to $14.0M while cash flow remained resilient.
Operating income declined 40.1% to $14.0 million, representing a 7.2% margin, as the revenue mix shift and operational challenges eroded profitability. Net income dropped sharply 89.4% to $1.2 million, with diluted EPS at $0.00. The year-over-year decrease in income tax expense stemmed mainly from lower income before taxes, though partially offset by a higher estimated annual effective tax rate and tax effects from equity awards.
Strategically, the quarter saw the launch of Employer Direct, a new platform to help employers bridge gaps in traditional insurance by integrating cash pricing for better affordability and access. Subscription offerings like GoodRx Gold, condition-specific programs launched in June 2025, and RxSmartSaver+ from July 2025 continued to define consumer engagement. No material changes occurred in liquidity needs or contractual commitments from the 2025 10-K, with future capital requirements tied to business growth, investment timing, sales and marketing scale, and risk factors outlined therein. This positions GoodRx to navigate disruptions while investing in diversified revenue streams like Pharma Direct and employer solutions.